InvestorsHub Logo
Followers 113
Posts 25553
Boards Moderated 4
Alias Born 02/01/2004

Re: MiamiGent post# 13332

Friday, 04/15/2016 9:13:02 AM

Friday, April 15, 2016 9:13:02 AM

Post# of 40503
Here is the Roche deal:

Roche

Roche & Inovio
Roche acquired an exclusive worldwide license to develop and commercialize Inovio’s hepatitis B (INO-1800) immunotherapy. Roche paid US $10 million upfront, in part for the hepatitis B rights, and paid a $3 million milestone payment in early 2015 for the launch of a phase I study of INO-1800. Roche is paying all clinical development costs and will make payments upon reaching certain development and commercial milestones. Inovio is entitled to receive up to double-digit tiered royalties on product sales.

Terrific!!

Nothing disgraceful that I can detect.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INO News